Alnylam Pharmaceuticals, Inc.

ALNY • Biotechnology

$233.29

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$32.25B

Growth

—

Cash Flow

2/5

Trend

Volatile

Evidence

Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$233.29

Change0.00%

Shares Out138.25M

Market Cap$32.25B

Enterprise Value$30.21B

52W Range197.81 - 495.55

Beta0.27

P/E39.92

P/S6.71

P/B23.82

P/FCF40.62

EV/Sales6.29

Price$233.29

Change0.00%

Shares Out138.25M

Market Cap$32.25B

Enterprise Value$30.21B

52W Range197.81 - 495.55

Beta0.27

P/E39.92

P/S6.71

P/B23.82

P/FCF40.62

EV/Sales6.29

EV/EBITDA59.03

EV/FCF38.05

Earnings Yield2.51%

FCF Yield2.46%

Dividend Yield0.00%

Gross Margin81.77%

Oper. Margin13.51%

Profit Margin8.45%

Debt/Eq1.62

Current Ratio2.76

Quick Ratio2.71

Target$347.23

Target Upside48.84%

Target Median$345.00

Target Range253.00 - 455.00

Volume9.75M

Avg Volume1.28M

EPS Surprise0.64

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

67/100

Financial Strength

Debt, cash, stability

62/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

20/100

Why this score▼

Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04

Analyst view

Analyst sentiment and price target

ALNY

Analyst sentiment

Based on 52 analyst votes · 2026-10-20

87/100

Bullish

Hold

Bearish

Price Target

2026-07-31

Low

$400.00

Mean

$438.50

Median

$436.50

High

$485.00

Company Overview

IPO: 6/1/2004

Industry: Biotechnology

P/B i: 23.82

Debt / Equity i: 1.62

Operating Margin: 13.51%

Net Margin: 8.45%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 1.62

Current Ratio: 2.76

Quick Ratio: 2.71

Status: Good

Insider Transactions

Recent executive and insider activity

Cravatt Benjamin

Transaction: 06/01/2026

OTHER

Change

Price

Not reported

Filing

06/03/2026

Type

OTHER

Cravatt Benjamin

Transaction: 06/01/2026

BUY

Change

+4,393

Price

$295.63

Filing

06/03/2026

Type

BUY

PYOTT DAVID E I

Transaction: 06/01/2026

SELL

Change

-3,830

Price

$70.20

Filing

06/03/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Cravatt Benjamin	OTHER	0	Not reported	06/01/2026	06/03/2026
Cravatt Benjamin	BUY	+4,393	$295.63	06/01/2026	06/03/2026
PYOTT DAVID E I	SELL	-3,830	$70.20	06/01/2026	06/03/2026
PYOTT DAVID E I	SELL	-17	$302.65	06/01/2026	06/03/2026
Arbuckle Stuart A	BUY	+671	Not reported	05/20/2026	05/22/2026
Arbuckle Stuart A	BUY	+1,441	$298.48	05/20/2026	05/22/2026
Ausiello Dennis A	BUY	+1,441	$298.48	05/20/2026	05/22/2026
Ausiello Dennis A	BUY	+671	Not reported	05/20/2026	05/22/2026
BRANDICOURT OLIVIER	BUY	+1,441	$298.48	05/20/2026	05/22/2026
BRANDICOURT OLIVIER	BUY	+671	Not reported	05/20/2026	05/22/2026
HAMBURG MARGARET A	BUY	+1,441	$298.48	05/20/2026	05/22/2026
HAMBURG MARGARET A	BUY	+671	Not reported	05/20/2026	05/22/2026
KELLOGG PETER N	BUY	+1,441	$298.48	05/20/2026	05/22/2026
KELLOGG PETER N	BUY	+671	Not reported	05/20/2026	05/22/2026
PYOTT DAVID E I	BUY	+1,441	$298.48	05/20/2026	05/22/2026
PYOTT DAVID E I	BUY	+671	Not reported	05/20/2026	05/22/2026
Reitan Colleen F	BUY	+1,441	$298.48	05/20/2026	05/22/2026
Reitan Colleen F	BUY	+671	Not reported	05/20/2026	05/22/2026
SCHULMAN AMY W	BUY	+1,802	$298.48	05/20/2026	05/22/2026
SCHULMAN AMY W	BUY	+838	Not reported	05/20/2026	05/22/2026

About the Company

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Source - link

Peers

ARGX BDX CAH CI COR EW IDXX REGN VEEV ZTS

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLC

Curated Wealth Partners LLC decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 96.9% in the quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,095 shares of the biopharmaceutical company's stock after selling 34,533 shares during the period.

Defense World

Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by First Citizens Bank & Trust Co.

First Citizens Bank and Trust Co. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,874 shares of the biopharmaceutical company's stock, valued at approximately $709,000. Several other hedge funds have also recently

Defense World

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the

GuruFocus

Alnylam vs. Ionis: Here's the Better Bad-News Buy

Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis experienced two pipeline setbacks on the same day in July.

The Motley Fool

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison

Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Onconetix (NASDAQ: ONCO - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 93.0% of Alnylam Pharmaceuticals shares

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-30	0.872	1.51	0.638
2026-02-12	1.16	0.82	-0.34
2025-10-30	0.561	2.9	2.339
2025-07-31	-0.54371	0.32	0.86371
2025-05-01	-0.89002	-0.01	0.88002
2025-02-13	-0.62	0.06	0.68
2024-10-31	-0.91663	-0.5	0.41663
2024-08-01	-1.07	0.56	1.63
2024-05-02	-1.12	-0.16	0.96
2024-02-15	-1.2	-1.1	0.1
2023-11-02	-1.34	1.15	2.49
2023-08-03	-1.72	-2.21	-0.49